Pictured: Ion Channel K2P1
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, February 9, 2012

Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Tuesday, February 7, 2012

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

Pictured: Memorial Sloan Kettering logo
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, February 6, 2012

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

Pictured: Charles Sawyers & Howard Scher
In the News
By Media Staff  |  Friday, February 3, 2012

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

Pictured: Marc Ladanyi & Laetitia Borsu
In the Lab
By Jim Stallard, MA, Writer/Editor  |  Wednesday, February 1, 2012

Memorial Sloan Kettering researchers have performed the first large-scale genetic analysis of several pediatric cancers, identifying mutations and potential targets for therapies to treat the cancers.

Finding
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, January 23, 2012

Research has shown that children who have experienced a sunburn at an early age are at almost double the risk for developing melanoma in adulthood. Now, a new study led by Memorial Sloan Kettering epidemiologist Stephen Dusza finds that most children do not regularly use sunscreen.

Pictured: Eric Pamer
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Friday, January 20, 2012

Infections are a common cause of complications in cancer patients. Now a Memorial Sloan Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.

Pictured: Michael Morris
In the Clinic
By Media Staff  |  Friday, January 13, 2012

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.

Pictured: Major Trends in Modern Cancer Research Seminar
Video
By Memorial Sloan Kettering  |  Thursday, January 12, 2012

Hundreds of high school students and teachers attended our sixth annual Major Trends in Modern Cancer Research seminar to learn about cutting-edge biomedical research and to engage with leading scientists.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
Feature
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, December 28, 2011

Years of innovative research, technology development, and facility expansion at Memorial Sloan Kettering have led to several new experimental treatments for people with cancer.

Pictured: Craig Thompson
Perspective
By Craig Thompson, MD, President and CEO  |  Friday, December 23, 2011

Since the signing of the National Cancer Act in 1971, tremendous progress has been made in preventing and treating cancer—though challenges remain.

Pictured: Hans-Guido Wendel
Profile
By Jim Stallard, MA, Writer/Editor  |  Tuesday, December 20, 2011

German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.

Pictured: Nancy Lee
In the Clinic
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, December 19, 2011

People with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy, according to an international study led by Memorial Sloan Kettering radiation oncologist Nancy Y. Lee.

Feature
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, December 15, 2011

Memorial Sloan Kettering scientists, physicians, and administrators are developing and commercializing research discoveries to generate more-effective and affordable cancer treatments.

Honor
By Media Staff  |  Wednesday, December 14, 2011

Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

Center News

Stay Informed

Get the latest information about cancer care and research every month.